Abstract

High-flow oxygen therapy is a novel technology in the treatment of hypoxemic respiratory failure (HRF). The effect in neonatal and pediatric population is well known, but its efficiency in the adult patient group is not well proven. This review tried to discuss various aspects of high-flow nasal cannula (HFNC) in terms of its components, effects, and the evidence available. High-flow nasal cannula is being used as the first choice of intervention in patients with acute HRF, especially in patients who does not have critical hypercapnia. Clinicians should be very selective while choosing the adult patients for HFNC.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.